for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Johnson & Johnson

JNJ.N

Latest Trade

138.36USD

Change

-4.79(-3.35%)

Volume

3,092,064

Today's Range

138.18

 - 

141.62

52 Week Range

109.17

 - 

157.00

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
143.15
Open
140.90
Volume
3,092,064
3M AVG Volume
127.25
Today's High
141.62
Today's Low
138.18
52 Week High
157.00
52 Week Low
109.17
Shares Out (MIL)
2,632.54
Market Cap (MIL)
376,848.50
Forward P/E
--
Dividend (Yield %)
2.82

Next Event

Johnson & Johnson at Credit Suisse Healthcare Conference (Virtual)

Latest Developments

更多

J&J Prepares To Resume Phase 3 Ensemble Trial Of Janssen Covid-19 Vaccine Candidate In U.S.

Genmab Announces IFM, Hovon And Janssen Achieve Positive Topline Results In Second Part Of Phase 3 Cassiopeia Study Of Daratumumab In Multiple Myeloma At Pre-Planned Interim Analysis

Janssen Receives Positive CHMP Opinion For Long-Acting Regimen For The Treatment Of Hiv

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry

Biotechnology & Drugs

Contact Info

1 Johnson And Johnson Plz

NEW BRUNSWICK, NJ

08933-0001

United States

+1.732.5242455

https://www.jnj.com/

Key Stats

1.94 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

76.5K

2018

81.6K

2019

82.1K

2020(E)

81.7K
EPS (USD)

2017

7.300

2018

8.180

2019

8.680

2020(E)

7.984
Price To Earnings (TTM)
22.91
Price To Sales (TTM)
4.66
Price To Book (MRQ)
5.84
Price To Cash Flow (TTM)
15.84
Total Debt To Equity (MRQ)
58.56
LT Debt To Equity (MRQ)
50.69
Return on Investment (TTM)
13.23
Return on Equity (TTM)
10.23

Latest News

Latest News

WRAPUP 8-AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to do same

AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday.

J&J preparing to resume U.S. trial of COVID-19 vaccine candidate

Oct 23 - Johnson & Johnson said on Friday it was preparing to resume a large clinical trial of its experimental COVID-19 vaccine in the United States after an independent safety panel recommended enrollments for the study.

Johnson & Johnson coronavirus vaccine trial to resume soon - Washington Post

Johnson & Johnson's coronavirus vaccine trial will resume very soon after investigators concluded a participant's illness was unrelated to the vaccine, the Washington Post reported on Friday, citing two people familiar with the matter. (Reporting by Munsif Vengattil; Editing...

EU signs supply deal with J&J on potential COVID-19 vaccine

The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.

EXCLUSIVE-U.S. trial of AstraZeneca COVID-19 vaccine may resume this week -sources

AstraZeneca Plc's COVID-19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a serious illness in a study participant, four sources told Reuters.

UPDATE 1-GSK-J&J's long-acting HIV injection gets EU panel endorsement

GlaxoSmithKline Plc said an injection of its cabotegravir drug given every two months, in combination with Johnson & Johnson's rilpivirine, was recommended for approval to treat HIV infections by a panel of the European health regulator.

GSK's long-acting HIV injection endorsed by EU panel

GlaxoSmithKline Plc said on Friday an injection of its cabotegravir drug given every two months along with Johnson & Johnson's rilpivirine was recommended for approval to treat HIV infections by a panel of the European health regulator.

GLOBAL MARKETS-Asian equities slip as vaccine trials, stimulus talks stall

Asian equities slipped on Wednesday as halted COVID-19 vaccine trials and an impasse in U.S. fiscal aid package talks soured risk appetite, while the greenback held on to gains as demand firmed for safe-harbour assets.

GLOBAL MARKETS-Asian equities set to slip as vaccine trials, stimulus talks stall

Asian equities were set to slip on Wednesday as halted COVID-19 vaccine trials and an elusive U.S. stimulus agreement weighed on investor sentiment, while the dollar rose from Tuesday's three-week low as demand firmed for safe-haven assets.

GLOBAL MARKETS-World stocks pause rally on J&J news, USD bounces from 3-week low

The U.S. dollar rose from a three-week low on Tuesday while shares in Europe and the United States eased, as news of a pause in Johnson & Johnson's COVID-19 vaccine trial led investors to take stock of recent rallies before chasing further gains.

UPDATE 2-J&J to contribute up to $5 billion to potential U.S. opioid settlement

Johnson & Johnson said on Tuesday it will contribute up to $1 billion more to a potential settlement of lawsuits alleging it and other companies fueled the U.S. opioid epidemic, bringing its total payment to $5 billion.

UPDATE 6-J&J says review of illness that led to coronavirus vaccine trial pause could take days

* J&J, AstraZeneca vaccines both based on adenoviruses (Adds comment from former FDA head, background, share move)

EMERGING MARKETS-Latam FX, stocks slide on COVID-19 vaccine uncertainty

Latin American currencies and stocks fell on Tuesday as global risk sentiment took a hit from Johnson & Johnson's move to pause its COVID-19 vaccine trials and on a worsening emerging market growth outlook from the International Monetary Fund. Markets were spooked by U.S...

US STOCKS SNAPSHOT-S&P 500, Dow slip on J&J vaccine worries; Apple, Amazon prop up Nasdaq

The S&P 500 and the Dow opened lower as a pause in Johnson & Johnson's COVID-19 vaccine trials weighed, while the Nasdaq rose ahead of major events scheduled for Apple and Amazon.com.

UPDATE 2-J&J raises profit forecast as trial halt weighs

Johnson & Johnson raised its annual profit forecast for the second time this year in quarterly results on Tuesday, a day after it was the second major drug company to call a temporary halt to trials of its experimental coronavirus vaccine.

Johnson & Johnson sales rise nearly 2% on cancer drug demand

Johnson & Johnson reported a 1.7% rise in third-quarter sales on Tuesday due to higher demand for its cancer drugs, a day after the company said it had paused its COVID-19 vaccine trials.

J&J COVID-19 vaccine study paused due to unexplained illness in participant - Stat News

Johnson & Johnson's COVID-19 vaccine study has been paused due to an unexplained illness in a study participant, Stat News reported on Monday, citing a document obtained by the news organization.

FACTBOX-EU tries to catch-up after U.S., UK spend billions to secure coronavirus vaccines

(Adds AstraZeneca's Canada and Thailand deals, RDIF deals with Uzbekistan, Egypt, India, Nepal and Brazil; Updates Johnson & Johnson's EU agreement) Oct 12 (Reuters) - The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies...

UPDATE 2-EU's potential COVID-19 vaccine doses top a billion with J&J deal

The European Union has sealed a deal with Johnson & Johnson to supply up to 400 million doses of its potential COVID-19 vaccine, as the bloc builds up stocks amid a global scramble to secure shots.

J&J to pay more than $100 mln to settle over 1,000 talc lawsuits: Bloomberg

Johnson & Johnson will pay more than $100 million to settle over 1,000 lawsuits that allege the company's Baby Powder caused cancer, Bloomberg news reported on Monday https://www.bloomberg.com/news/articles/2020-10-05/j-j-to-pay-more-than-100-million-to-end-over-1-000-talc-suits...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up